Delivery Order SPE2DB24D9315-SPE2DB25FFWKR
Award Date
5/13/25
Potential Completion Date
6/4/25
Potential Value
$8.2K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $8,220.68, is for the delivery of Stelara 90 mg/ml syringes. The contract has an ultimate completion date of April 28, 2025 and was awarded on April 7, 2025. DMS Pharmaceutical Group Inc. is the prime contractor, and there are no major subcontractors mentioned. This delivery order is part...
This is a $8,220.68 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is for the supply of Stelara 90 mg/ml syringes to support the medical supply needs of military health facilities. The contract has an ultimate completion date of May 29, 2025. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $8,220.68 order is for the supply of Stelara 90 mg/ml syringes. The contract has an ultimate completion date of May 6, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a range of...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $8,220.68 contract is for the delivery of STELARA 90 MG/ML SYRINGE with a period of performance through March 20, 2025. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue firm fixed-price delivery orders...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $8,220.68 contract is for the delivery of Stelara 90 mg/ml syringes to support the medical supply needs of military health facilities. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $8,220.68 contract is for the delivery of Stelara 90 mg/ml syringe medication and has a performance period through May 29, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with DLA under the SPE2DB program, enabling the agency to issue delivery orders for a broad portfolio of...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $8,220.68, is for the delivery of Stelara 90 mg/ml syringes to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of Stelara 90 mg/ml syringes. The award has a ceiling value of $16,441.36 and a period of performance through May 22, 2025. DMS Pharmaceutical Group holds a single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which enables the agency to issue firm fixed-price...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of the drug Stelara 90 mg/ml syringe. The award, valued at $7,108.82, has a period of performance through May 10, 2024. This delivery order is placed under a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group worth up to $499,999,999, which allows the DLA to issue firm fixed-price orders for a wide...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract has a ceiling value of $8,220.68 and is for the delivery of Stelara 90 mg/ml syringes. The contract is a firm fixed-price delivery order with a period of performance through March 5, 2025. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at...